Computational Modeling of Drug Delivery for Treatment of Age-Related Macular Degeneration

2018 ◽  
pp. 539-545
Author(s):  
N. G. Dimitrioglou ◽  
M. E. Kavousanakis ◽  
D. T. Hatziavramidis
Keyword(s):  
Drug Delivery ◽  
Computational Modeling ◽  
Macular Degeneration ◽  
Age Related Macular Degeneration ◽  
Age Related

scholarly journals Computational modeling of retinal hypoxia and photoreceptor degeneration in patients with age-related macular degeneration

PLoS ONE ◽  
2019 ◽  
Vol 14 (6) ◽  
pp. e0216215 ◽  
Author(s):  
Kevin J. McHugh ◽  
Dian Li ◽  
Jay C. Wang ◽  
Leon Kwark ◽  
Jessica Loo ◽  
...  
Keyword(s):  
Computational Modeling ◽  
Macular Degeneration ◽  
Age Related Macular Degeneration ◽  
Photoreceptor Degeneration ◽  
Age Related

scholarly journals Biotechnology and Biomaterial-Based Therapeutic Strategies for Age-Related Macular Degeneration. Part I: Biomaterials-Based Drug Delivery Devices

2020 ◽  
Vol 8 ◽  
Author(s):  
Nahla Jemni-Damer ◽  
Atocha Guedan-Duran ◽  
María Fuentes-Andion ◽  
Nora Serrano-Bengoechea ◽  
Nuria Alfageme-Lopez ◽  
...  
Keyword(s):  
Drug Delivery ◽  
Macular Degeneration ◽  
Therapeutic Strategies ◽  
Age Related Macular Degeneration ◽  
Age Related ◽  
Drug Delivery Devices

An Implantable Device Design Concept for Ocular Drug Delivery

2012 ◽  
Author(s):  
Jae-Hwan Lee ◽  
Ramana M. Pidaparti
Keyword(s):  
Drug Delivery ◽  
Macular Degeneration ◽  
Ocular Drug Delivery ◽  
Eye Diseases ◽  
Age Related Macular Degeneration ◽  
Intravitreal Injections ◽  
Delivery Device ◽  
Drug Delivery Device ◽  
Age Related ◽  
Intraocular Hemorrhage

New drugs for curing eye diseases have been developing for a decade and are very unique for each eye diseases such as glaucoma, cataracts, and age-related macular degeneration (AMD). It is estimated that 1.6 million adults in the US over the age of 50 and above suffer from age-related macular degeneration and about 200,000 cases are diagnosed annually. Worldwide, about 500,000 cases are diagnosed annually [1]. Drugs currently utilized for AMD are delivered via repeated intravitreal injections of the drug into the eye. Risks of repeated intravitreal injections can include intraocular infections (endophthalmitis), intraocular hemorrhage, and retinal detachment. Also, reducing the frequency of dosing will clearly benefit the patient by reducing the need for risky intravitreal injections and improving the pharmacokinetics of the drug in the eye. The eye disease of posterior segment (Dry and Wet) has limits to deliver the drug to retina region using typical eye drop. The drug injection using a needle with syringe can deliver but it barely provide right amount of doses, or over doses that may cause more severe problem such as swelling, fatigue, and damaging photoreceptor molecules. Furthermore, most drugs run away in a month so that repeated injection is necessary. Developing an implantable drug delivery device will help reduce the costs and risks associated with frequent injections and facilitate delivering the drug in a controlled manner and in the required amounts, and improve therapeutic efficacy and safety of drugs. This study focuses on the design, simulation and development of the implantable ocular drug delivery device.

scholarly journals Nanotechnology for Age-Related Macular Degeneration

Pharmaceutics ◽  
2021 ◽  
Vol 13 (12) ◽  
pp. 2035
Author(s):  
Bo Yang ◽  
Ge Li ◽  
Jiaxin Liu ◽  
Xiangyu Li ◽  
Shixin Zhang ◽  
...  
Keyword(s):  
Drug Delivery ◽  
Gene Therapy ◽  
Macular Degeneration ◽  
Vision Loss ◽  
Cumulative Risk ◽  
Age Related Macular Degeneration ◽  
Delivery Methods ◽  
Age Related ◽  
Therapy Strategies ◽  
Endothelial Growth Factor

Age-related macular degeneration (AMD) is a degenerative eye disease that is the leading cause of irreversible vision loss in people 50 years and older. Today, the most common treatment for AMD involves repeated intravitreal injections of anti-vascular endothelial growth factor (VEGF) drugs. However, the existing expensive therapies not only cannot cure this disease, they also produce a variety of side effects. For example, the number of injections increases the cumulative risk of endophthalmitis and other complications. Today, a single intravitreal injection of gene therapy products can greatly reduce the burden of treatment and improve visual effects. In addition, the latest innovations in nanotherapy provide the best drug delivery alternative for the treatment of AMD. In this review, we discuss the development of nano-drug delivery systems and gene therapy strategies for AMD in recent years. In addition, we discuss some novel targeting strategies and the potential application of these delivery methods in the treatment of AMD. Finally, we also propose that the combination of CRISPR/Cas9 technology with a new non-viral delivery system may be promising as a therapeutic strategy for the treatment of AMD.

Drug delivery techniques for treating age-related macular degeneration

2013 ◽  
Vol 11 (1) ◽  
pp. 61-68 ◽  
Author(s):  
Stephen G Schwartz ◽  
Ingrid U Scott ◽  
Harry W Flynn ◽  
Michael W Stewart
Keyword(s):  
Drug Delivery ◽  
Macular Degeneration ◽  
Age Related Macular Degeneration ◽  
Age Related ◽  
Delivery Techniques

scholarly journals Nanotechnology-based drug delivery treatments and specific targeting therapy for age-related macular degeneration

2015 ◽  
Vol 78 (11) ◽  
pp. 635-641 ◽  
Author(s):  
Tai-Chi Lin ◽  
Kuo-Hsuan Hung ◽  
Chi-Hsien Peng ◽  
Jorn-Hon Liu ◽  
Lin-Chung Woung ◽  
...  
Keyword(s):  
Drug Delivery ◽  
Macular Degeneration ◽  
Age Related Macular Degeneration ◽  
Targeting Therapy ◽  
Specific Targeting ◽  
Age Related
Sign in / Sign up

Export Citation Format

Share Document